- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05180916
Priming the Epileptic Brain: tVNS to Improve Efficacy of add-on AED in Patients With Focal Epilepsy (PREP)
Priming the Epileptic Brain - Determining the Effect of Temporarily Addition of Transcutaneous Vagal Nerve Stimulation When Starting an add-on AED (in This Case Brivaracetam) in Patients With Refractory Focal Epilepsy
Studieöversikt
Detaljerad beskrivning
Background of the study: The most prevalent neurological disorder with also immense burden of disease, epilepsy, is in over 30 percent of patients difficult to treat. The ideal treatment regime would give complete control of disease in an early stage, not only for patient well-being, but also to prevent the onset of persistent pathologic epileptic networks in the brain. The first step in treatment is the trial, and error, of multiple anti-epileptic drugs (AEDs), while invasive brain stimulation (BS) techniques with network modulating properties are saved as a last resort. The investigators hypothesize that pharmacotherapeutic treatment of epilepsy can be more successful after "priming" (preparing) the brain using BS as a short-term neuromodulation treatment. The limitation of testing this hypothesis is the invasive aspect of the most used classic vagal nerve stimulation (VNS) treatment for epilepsy, but the recent development of transcutaneous vagal nerve stimulation (tVNS) offered a possibility to combine chemical and electrical modulation in an earlier stage of disease, which is not tested before.
Objective of the study: Determine the priming effect on the epileptic brain of tVNS, to make it more susceptible to add-on treatment with Brivaracetam (BRV), an AED. In addition, the investigators aim to visualize these changes in the brain because of priming, possibly altered network-organisation.
Study design: Randomized Controlled Trial. Study population: Adults with a refractory (continuing of seizures despite 2 tried AEDs) focal epilepsy and therefore have an indication for start of Brivaracetam. Intervention (if applicable): One group receives transcutaneous vagal nerve stimulation (tVNS) 4 hours daily for the first 3 months of brivaracetam treatment. Primary study parameters/outcome of the study: Scoring on a composite index combining seizure reduction, improvement of cognition and quality of life. Secondary study parameters/outcome of the study (if applicable): Seizure reduction, seizure freedom rates, seizure severity, cognition, mood state, adverse events tVNS and brivaracetam, change in brain network properties.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness (if applicable): Besides minor temporary side effects no risk is attributed to tVNS. Because of the study one extra visit is necessary, besides regular clinical follow-up. The 3 visits do require some more time than usual because of the questionnaires, MRI and short cognitive tests. The burden of the telephone calls is very limited, since it only consists of a few short questions. Patients with claustrophobia are excluded, but the requirement of lying still can be somewhat uncomfortable. The eye tracking device uses a camera in the video screen, with no burden at all.
Studietyp
Inskrivning (Förväntat)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Angelique A Stuurman, Msc
- Telefonnummer: 0031402279777
- E-post: prep@tue.nl
Studera Kontakt Backup
- Namn: Rob R Mestrom, Dr
- Telefonnummer: 0031402279777
- E-post: prep@tue.nl
Studieorter
-
-
Noord Brabant
-
Heeze, Noord Brabant, Nederländerna, 5590 AB
- Rekrytering
- Stichting Kempenhaeghe
-
Kontakt:
- Angelique Stuurman
- Telefonnummer: 0031 0402279777
- E-post: prep@tue.nl
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Focal epilepsy which is refractory (at least 2 different AEDs tried) and therefore has an indication for start of brivaracetam
- Age ≥ 18 years.
- IQ > 70 defined as any form of secondary education
Exclusion Criteria:
- - Inclusion not possible within 2 weeks after start of brivaracetam
- History of a progressive cerebral disorder (neurodegenerative diseases, tumours)
- History of psychogenic nonepileptic seizures (PNES)
- Inability to provide informed consent
- Any contra-indication for brivaracetam
- Current or recent use (exposed ≤ 90 days)
- Current or recent use (exposed ≤ 90 days) of levetiracetam
- Current treatment with neurostimulation
- Inability of handling the tVNS device personally
- Subjects that have a current diagnosis of cardiac arrhythmic disease
- Any contraindication for tVNS: pregnancy, active implants (such as cardiac pacemakers of cochlear implants) or cerebral shunts (e.g. ventriculo-peritoneal shunts with valve)
- Any contraindication for MRI: metallic foreign body, pacemaker, claustrophobia, pregnancy
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Brivaracetam + Transcutaneous vagal nerve stimulation
Start of Brivaracetam (treatment as usual), combined with tVNS in the first 3 months of treatment
|
Cerbomed NEMOS
|
Inget ingripande: Brivaracetam
Start of Brivaracetam (treatment as usual)
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Epilepsy frequency
Tidsram: 6 months
|
Seizure reduction (in % at 3 and 6 months in respect to baseline)
|
6 months
|
Epilepsy frequency
Tidsram: 6 months
|
Seizure freedom rates (defined as the percentage of subjects with 100% reduction from baseline seizure frequency)
|
6 months
|
Seizure severity
Tidsram: 6 months
|
Assessed by the National Hospital Seizure Severity Scale - NHS3, comparing scores at 3 and 6 months to baseline).
Score range 1-27 (higher score = more severe).
|
6 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Brain networks
Tidsram: 3 months
|
Detect changes in network properties by comparing fMRI (functional MRI) data at 3 months with baseline (independent component analysis)
|
3 months
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Marian M Majoie, Prof. Dr., ACE Kempenhaeghe
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- PREP_001
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Fokal epilepsi
-
Universitätsklinikum Hamburg-EppendorfCentre Hospitalier Universitaire de Nice; Olympus Corporation; Keio University och andra samarbetspartnersAvslutadGastric Focal LesionFrankrike
-
Neurocrine BiosciencesAvslutadFocal Onset Anfall | Focal Debut EpilepsiSpanien, Australien, Belgien, Tjeckien, Frankrike, Ungern, Italien
-
Neurocrine BiosciencesAvslutadFocal Onset Anfall | Focal Debut EpilepsiSpanien, Belgien, Tjeckien, Frankrike, Italien, Australien, Ungern, Storbritannien
-
Zealand University HospitalOkändHyperhidros Primär Focal AxillaDanmark
-
InMode MD Ltd.RekryteringHyperhidros Primär Focal AxillaIsrael, Förenta staterna
-
University of Sao PauloRekryteringHyperhidrosis Primär Focal PalmsBrasilien
-
Merete HaedersdalAvslutadHyperhidros Primär Focal AxillaDanmark
-
Medy-ToxAvslutadHyperhidros Primär Focal AxillaKorea, Republiken av
-
All India Institute of Medical Sciences, BhubaneswarAvslutad
-
Allegro Ophthalmics, LLCAvslutadSymtomatisk Focal Vitreomacular AdhesionFörenta staterna
Kliniska prövningar på TVNS
-
Shanghai Mental Health CenterAnmälan via inbjudan
-
University of FloridaAvslutadStress, psykologisk | Sova | Vagus nervstimulering | Mindfulness | Transkutan elektrisk nervstimuleringFörenta staterna
-
Foundation for Prader-Willi ResearchRTI InternationalRekryteringPrader-Willis syndromFörenta staterna
-
Istituti Clinici Scientifici Maugeri SpARekryteringHjärtsvikt Med Bevarad Ejection Fraktion | Hjärtsvikt Med MellanregisterutkastningsfraktionItalien
-
University of California, Los AngelesUniversity of OklahomaRekryteringFörmaksflimmerFörenta staterna
-
University GhentAvslutad
-
Krankenhaus HetzelstiftJohannes Gutenberg University Mainz; Deutsche Stiftung für HerzforschungRekrytering
-
Fondazione Toscana Gabriele MonasterioAzienda Ospedaliera Città della Salute e della Scienza di TorinoHar inte rekryterat ännuHjärtsvikt | Hjärtsvikt Med Minskad Ejection Fraktion | Hjärtsvikt Med MellanregisterutkastningsfraktionItalien
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH)RekryteringMajor depressiv sjukdomFörenta staterna
-
Stanford UniversityIndragenPrader-Willis syndrom | Socialt beteende